0000899243-20-011283.txt : 20200424
0000899243-20-011283.hdr.sgml : 20200424
20200424161611
ACCESSION NUMBER: 0000899243-20-011283
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200422
FILED AS OF DATE: 20200424
DATE AS OF CHANGE: 20200424
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: El-Hibri Fuad
CENTRAL INDEX KEY: 0001380185
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33137
FILM NUMBER: 20815144
MAIL ADDRESS:
STREET 1: 2273 RESEARCH BLVD, SUITE 400
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Emergent BioSolutions Inc.
CENTRAL INDEX KEY: 0001367644
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 141902018
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 400 PROFESSIONAL DR, SUITE 400
CITY: GAITHERSBURG
STATE: MD
ZIP: 20879
BUSINESS PHONE: 240-631-3200
MAIL ADDRESS:
STREET 1: 400 PROFESSIONAL DR, SUITE 400
CITY: GAITHERSBURG
STATE: MD
ZIP: 20879
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-04-22
0
0001367644
Emergent BioSolutions Inc.
EBS
0001380185
El-Hibri Fuad
400 PROFESSIONAL DRIVE, SUITE 400
GAITHERSBURG
MD
20879
1
1
1
0
Chairman
Common Stock
2020-04-22
4
S
0
20000
66.81
D
1289523
D
Common Stock
2020-04-23
4
S
0
20000
68.49
D
1269523
D
Common Stock
4344250
I
By Intervac, L.L.C.
Common Stock
1524155
I
By Biovac, L.L.C.
The transaction was made by the Reporting Person pursuant to a trading plan adopted by Fuad El-Hibri Nancy El-Hibri JTWROS on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934.
The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.25 to $68.19.
The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.73 to $70.30.
Mr. El-Hibri's wife, individually, and Mr. and Mrs. El-Hibri, as tenants by the entirety, collectively hold an aggregate 40.65% equity interest in Intervac, L.L.C., which in turn is the direct owner of 4,344,250 shares of the Issuer's common stock. Mr. El-Hibri disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Intervac, L.L.C. for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein.
Mr. El-Hibri, individually, and Mr. and Mrs. El-Hibri, as tenants by the entirety, collectively hold an aggregate 89.2% equity interest in Biovac, L.L.C, which in turn is the direct owner of 1,524,155 shares of the Issuer's common stock. Mr. El-Hibri disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Biovac, L.L.C. for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein.
/s/ Carl A. Valenstein, attorney-in-fact
2020-04-24